Allogene Therapeutics, Inc. (ALLO)

Allogene Therapeutics' stock has experienced significant positive movement, with a 110.58% increase in the past six months. Positive interim data from the ALPHA3 trial led to a stock surge, while a public offering caused short-term adjustments. Trial expansion and pre-clinical data publication also influenced the stock. Analyst ratings have been mixed, with some firms increasing price targets and others maintaining "sell" or "hold" ratings.

As a clinical-stage biotechnology company, Allogene Therapeutics, Inc. does not experience typical demand seasonality. Demand for its products, once approved, will be driven by disease prevalence, clinical efficacy, regulatory approvals, and physician adoption, rather than seasonal fluctuations.

Allogene Therapeutics, Inc. is a clinical-stage immuno-oncology company focused on developing and commercializing genetically engineered allogeneic T cell therapies (AlloCAR T products). Operating in the Healthcare sector and Biotechnology industry, Allogene aims to provide readily available, reliable, and scalable "off-the-shelf" CAR T cell candidates. Key products include Cemacabtagene ansegedleucel (cema-cel) for large B-cell lymphoma, ALLO-316 for renal cell carcinoma, and ALLO-329 for autoimmune diseases.

Allogene Therapeutics, Inc. is headquartered in South San Francisco, California. Its clinical trial activities extend beyond the United States, with the Phase 2 ALPHA3 study expanding to include sites in South Korea and Australia.

Allogene Therapeutics' brand reputation has been positively influenced by clinical and scientific advancements. Strong interim data from the ALPHA3 trial and the publication of preclinical data for ALLO-329 have bolstered the company's reputation. Trial expansions and FDA Fast Track Designations also underscore the potential of Allogene's investigational products. The company's focus on scalability and accessibility reinforces a positive image of addressing unmet patient needs.

Allogene Therapeutics, Inc. has a mixed ownership structure, including institutional, individual, and retail investors. Major institutional owners include Pfizer Inc., Tpg Gp A, Llc, and BlackRock, Inc. Pfizer Inc. is also the largest individual shareholder, owning 9.04% of the company, while CEO David Chang owns 3.8% of the company's shares. Insiders collectively own approximately 6.95% of the company's stock.